<DOC>
	<DOC>NCT01148446</DOC>
	<brief_summary>The study has the purpose to compare R-CHOP versus R-mini-CEOP in elderly patients (&gt;65 years) with Diffuse Large B Cell Lymphoma (DLBCL).</brief_summary>
	<brief_title>R-CHOP Versus R-mini-CEOP in Elderly Patients(&gt;65)With DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1. Patients with untreated DLBCL aged 66 to 80 years without major accompanying diseases and considered as "non frail". 2. Patients were classified as "non frail" (fit) if they had ADL (Activity of Daily Living) score of 6 less than three grade 3 Cumulative Illness Rating Score for Geriatrics (CIRSG) comorbidities and no grade 4 comorbidities absence of geriatric syndrome 3. Patients HIV negativity; 4. Concurrent malignancy; 5. Written Informed Consent. All other patients were classified as "unfit", and were excluded from randomization</criteria>
	<gender>All</gender>
	<minimum_age>66 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>R-CEOP</keyword>
	<keyword>Elderly patients</keyword>
</DOC>